1 / 38

The Novel Oral Anticoagulants

. I have no financial disclosure.. Acute venous thromboembolism. Incidence 1-2/1000 in the general populationRecurrence is one of the major complicationsWith full anticoagulation, risk of recurrence in the first 6-12 months 25%->3%Risk of recurrence remains 5-10% within the first year after the d

luka
Télécharger la présentation

The Novel Oral Anticoagulants

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. The Novel Oral Anticoagulants Tzu-Fei Wang 2/11/11

    2. I have no financial disclosure.

    3. Acute venous thromboembolism Incidence 1-2/1000 in the general population Recurrence is one of the major complications With full anticoagulation, risk of recurrence in the first 6-12 months 25%->3% Risk of recurrence remains 5-10% within the first year after the discontinuation of anticoagulation Standard of therapy: Heparin LMWH Warfarin After first year, annual major bleeding risk with coumadin is 1-2%/yearAfter first year, annual major bleeding risk with coumadin is 1-2%/year

    4. Advantage Low cost Effective (if done the right way) Disadvantage Narrow therapeutic index, requiring frequent blood draws and monitoring Multiple drug and/or food interactions Variability in dose response Slow onset Warfarin- the old anticoagulant

    5. New kids on the block

More Related